Calidi Biotherapeutics Showcases CLD-401 at SITC
Calidi Biotherapeutics, Inc. (NYSE: CLDI), a clinical-stage biotechnology firm, recently presented impactful new data regarding its lead therapeutic candidate CLD-401 during the Society for Immunotherapy of Cancer (SITC) Annual Meeting. This presentation highlighted the innovative capabilities of Calidi’s RedTail platform, which is focused on developing targeted genetic medicines.
Understanding CLD-401
At the forefront of Calidi's developments is CLD-401, an oncolytic virus engineered to specifically target metastatic tumors. It is designed to replicate within tumor cells exclusively, which plays a crucial role in triggering an immune response at the site of the tumor. This response is due in part to the high expression levels of IL-15 superagonist, a cytokine crucial for activating NK (natural killer) and T-cell responses within the tumor microenvironment.
Positive Outcomes from Research
According to Dr. Antonio F. Santidrian, Chief Scientific Officer at Calidi, recent data from syngeneic murine models illustrate that their RedTail platform successfully evades immune clearance following systemic delivery. The platform has shown promise in locating and replicating exclusively within tumor cells located in metastatic sites. As Dr. Santidrian states, this is a significant step forward in the field of cancer treatment.
Impressive Results of IL-15 Superagonist
In these models, levels of IL-15 superagonist detected in the tumor microenvironment after systemic administration were found to be comparable to those achieved through localized methods. Dr. Eric Poma, the Chief Executive Officer, shared insights on these findings, emphasizing that the concentrations observed in tumor tissues were significantly higher than those found circulating in serum or organs.
Future Developments for CLD-401
Calidi is actively engaged in IND-enabling studies for CLD-401, with plans to submit an Investigational New Drug application by the end of 2026. The company is also seeking strategic partnerships to expedite the clinical development phase, enhancing the potential for the RedTail platform to have a broader impact.
Investor Day Insights
This year's SITC meeting was significant not only for the data shared but also for the investor day that Calidi conducted. Esteemed members of its Scientific Advisory Board spoke at this event, including Dr. Dimitri Zamarin, a leader in virotherapy, and Dr. John Wrangle, who has contributed groundbreaking work on IL-15 superagonist therapy. Their discussions underscored the unique attributes and potential of CLD-401 and the RedTail platform.
About Calidi Biotherapeutics
Calidi Biotherapeutics is at the cutting edge of cancer treatment, using advanced technologies to address significant unmet medical needs in diseases such as non-small cell lung cancer and head and neck cancer. The company's RedTail platform is engineered to not only deliver viral therapies effectively but also to enhance the immune response against tumors.
Conclusion
As Calidi continues its development of CLD-401 and explores partnerships, the implications of its research could reshape treatments for individuals affected by various types of metastatic cancers. The ongoing studies and results from events like the SITC Annual Meeting inform us of the promising advancements on the horizon.
Frequently Asked Questions
What is CLD-401?
CLD-401 is an oncolytic virus developed by Calidi Biotherapeutics designed to target metastatic tumors and induce a strong immune response.
How does CLD-401 work?
It selectively replicates in tumor cells, promoting a localized immune response while minimizing systemic exposure to the treatment.
What are the future plans for CLD-401?
Calidi aims to submit an IND application for CLD-401 by the end of 2026 while seeking strategic partnerships to accelerate its clinical development.
Who are the key speakers at the investor day?
Notable speakers included Dr. Dimitri Zamarin and Dr. John Wrangle, who presented insights on CLD-401 and its potential in therapy.
What types of cancer does CLD-401 target?
Currently, CLD-401 is targeting non-small cell lung cancer, head and neck cancers, and other tumors with high unmet medical needs.
